CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China
SHENZHEN, CHINA – China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that the New Drug Application (NDA) in China for the Seasonal Allergic Rhinitis (SAR) indication of MG-K10 (generic name: Comekibart Injection, “MG-K10” or the “Product”), a Class 1 innovative drug anti-IL-4Rα humanized monoclonal antibody injection, for which the Group holds co-development rights (excluding the indication of atopic dermatitis (AD)) and exclusive commercialization rights, was accepted by the National Medical Products Administration of China (NMPA) on 23 April 2026. The Product is proposed for the treatment of adult patients with moderate-to-severe seasonal allergic rhinitis whose symptoms remain inadequately controlled after treatment with intranasal corticosteroids.
The a...
